Experiences in Engaging the Public on Biotechnology Advances and Regulation by M. Megan Quinlan et al.
February 2016 | Volume 4 | Article 31
Review
published: 02 February 2016
doi: 10.3389/fbioe.2016.00003
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org
Edited by: 
Andrew F. Roberts, 
International Life Sciences Institute 
Research Foundation, USA
Reviewed by: 
Gerald Epstein, 
U.S. Department of Homeland 
Security, USA 
Morven McLean, 
International Life Sciences Institute 
Research Foundation, USA
*Correspondence:
M. Megan Quinlan  
m.quinlan@imperial.ac.uk
Specialty section: 
This article was submitted to 
Biosafety and Biosecurity, 
a section of the journal 
Frontiers in Bioengineering and 
Biotechnology
Received: 06 August 2015
Accepted: 07 January 2016
Published: 02 February 2016
Citation: 
Quinlan MM, Smith J, Layton R, 
Keese P, Agbagala MLU, 
Palacpac MB and Ball L (2016) 
Experiences in Engaging the Public 
on Biotechnology Advances 
and Regulation. 
Front. Bioeng. Biotechnol. 4:3. 
doi: 10.3389/fbioe.2016.00003
experiences in engaging the Public 
on Biotechnology Advances and 
Regulation
M. Megan Quinlan1* , Joe Smith2 , Raymond Layton3 , Paul Keese4 ,  
Ma. Lorelie U. Agbagala5 , Merle B. Palacpac5 and Louise Ball6
1 Centre for Environmental Policy, Imperial College London, London, UK, 2 Advisor in Regulation, Science and Government 
(Formerly affiliated with the Office of the Gene Technology Regulator), Canberra, ACT, Australia, 3 Industry Affairs and 
Regulatory, DuPont Pioneer, Johnston, IA, USA, 4 Office of the Gene Technology Regulator, Canberra, ACT, Australia, 
5 Bureau of Plant Industry, Post Entry Quarantine Station, Los Baños, Philippines, 6 Department for Environment, Food and 
Rural Affairs, London, UK
Public input is often sought as part of the biosafety decision-making process. Information 
and communication about the advances in biotechnology are part of the first step to 
engagement. This step often relies on the developers and introducers of the particular 
innovation, for example, an industry-funded website has hosted various authorities to 
respond to questions from the public. Alternative approaches to providing information 
have evolved, as demonstrated in sub-Saharan Africa where non-governmental organi-
zations and associations play this role in some countries and subregions. Often times, 
those in the public who choose to participate in engagement opportunities have opinions 
about the overall biosafety decision process. Case-by-case decisions are made within 
defined regulatory frameworks, however, and in general, regulatory consultation does 
not provide the opportunity for input to the overall decision-making process. The various 
objectives on both sides of engagement can make the experience challenging; there are 
no clear metrics for success. The situation is challenging because public input occurs 
within the context of the local legislative framework, regulatory requirements, and the 
peculiarities of the fairly recent biosafety frameworks, as well as of public opinion and 
individual values. Public engagement may be conducted voluntarily, or may be driven 
by legislation. What can be taken into account by the decision makers, and therefore 
what will be gathered and the timing of consultation, also may be legally defined. Several 
practical experiences suggest practices for effective engagement within the confines of 
regulatory mandates: (1) utilizing a range of resources to facilitate public education and 
opportunities for understanding complex technologies; (2) defining in advance the goal 
of seeking input; (3) identifying and communicating with the critical public groups from 
which input is needed; (4) using a clearly defined approach to gathering and assessing 
what will be used in making the biosafety decision; and (5) communicating using clear 
and simple language. These practices create a foundation for systematic methods to 
gather, acknowledge, respond to, and even incorporate public input. Applying such best 
practices will increase transparency and optimize the value of input from the public.
Keywords: GM, GM crops, GM animals, environmental risk assessment, communication, public engagement, 
consultation, regulation
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iNTRODUCTiON
Public involvement is a critical part of the development, evalua-
tion, and acceptance of any new technology. It has been considered 
to be especially important as part of the biosafety decision-
making process and is included in the Cartagena Protocol on 
Biosafety (referred to below as the Protocol) to the Convention on 
Biological Diversity (CBD) (UNEP, 2000), specifically in Article 
23. However, the inclusion of public participation in the Protocol 
is linked to the sovereignty of countries to determine how best 
to do that. Without details on the best approach,1 the Protocol 
leaves much to the terms and conditions of national biosafety 
frameworks and national decision makers (Mackenzie et  al., 
2003; Toczeck Skarlatakis and Kinderlerer, 2013).
A critical point is that most state-led engagement approaches 
the introduction of a novel technology in terms of public good and 
the mandate for maintaining biosafety. In the governmental sec-
tor, gaining broad support for the biosafety framework may occur 
as a political process, rather than as part of regulatory decision 
making (Wohlers, 2010). In an early review of the US biosafety 
framework for transgenic plants, one conclusion was that using 
risk analysis to make scientifically informed decisions regarding 
safety as well as to legitimize the decision process to the public cre-
ates a tension and can itself skew the process [emphasis added] 
(National Research Council, 2002). Using public consultation as 
a means to reduce risks posed to a project or outcome, including 
risk related to lack of public acceptance, can also backfire (State 
of Victoria, 2005). More encouragingly, engaging the public may 
provide a means of addressing long-held concerns, which had not 
even been articulated until the consultation, but which may be 
meaningfully addressed (Marris, 2001). These conflicting objec-
tives and potential outcomes highlight what the authors observe 
to be an ever increasing tension between decision making based 
entirely on scientific evidence and decision making that is defined 
by societal values (Frewer et al., 2004; Ching, 2007). The integra-
tion of science and societal values is necessary for broader policy, 
but who are the actors and when is the moment to introduce 
considerations outside of scientific evidence?
This article aims to support those tasked with decision making 
by giving a general, pragmatic overview of practices for capturing 
and addressing public input regarding the decision process or to 
individual cases in the context of biotechnology. (The authors do 
not attempt to analyze larger questions on theory of public engage-
ment, the case-by-case decision-making approach generally used, 
or national sovereignty in the details of public consultation.) It 
is widely agreed that there is no single best approach to public 
involvement in decision making, particularly for complex or 
controversial issues. The developers and/or introducers of a new 
technology, the overall government, and the regulators of these 
introductions may seek public input for various reasons. As laid 
out in Box 1, it is imperative to understand and define the pur-
pose of any exchange on biotechnology, or other complex issues, 
1Recent work through the Cartagena Protocol process on public participation 
in biosafety decisions, including comments on best practices, is available at the 
Biosafety Clearing-House. This is summarized at http://bch.cbd.int/protocol/
cpb_art23_info.shtml
before selecting an approach (Nuffield Council on Bioethics, 
2012; Navarro et  al., 2013; Biosafety Clearing-House, 2014a). 
Furthermore, the appropriate implementer of the public involve-
ment process, and its timing and scale, are determined by the 
objective of the engagement and impacts on the outcome.
The discussion originated as presentations in a session on the 
same topic at the 13th International Symposium on Biosafety 
of Genetically Modified Organisms (Cape Town, South Africa, 
November 9–13, 2014), which was attended by a number of indi-
viduals responsible for regulatory decisions in their own country.
As background to this article, experts involved in public 
engagement were asked the questions in Table 1, which served as 
the basis for the presenters’ selection of cases. A broader survey 
of such individuals using these questions would provide further 
food for thought.
Each of the experts presenting recognized the importance of 
systematic methods to gather, acknowledge, respond to, and, as 
appropriate, incorporate public input. Communication has been 
made more effective by translating scientific jargon to deliver 
a more understandable message. Structured approaches have 
been developed to more successfully gather and interpret public 
input and then communicate the results in a transparent fashion. 
Communications technology (use of the internet and social 
media) has been utilized to shift from a one-way communica-
tion of scientific data to a full dialog where the public can ask 
questions that are then answered by technical experts (Society of 
Biology, 2011).
The appropriate metric for gauging success of public involve-
ment is not clear. Some argue that only participation that can lead 
to policy change is meaningful [e.g., Ching (2007)], yet when a 
framework is set, the value of participation is to play a role of 
broadening the perspectives included in the case in hand (Dietrich 
and Schibeci, 2003). Most agree that identifying, informing, and 
engaging with the public, and its many sectors, is the first step. The 
experiences and examples of practices for involving the public 
in decisions are more fully discussed in the three case studies 
presented in Section “Involving the Public in Decision Making.”
iNFORMiNG AND eNGAGiNG THe PUBLiC 
AS A FiRST STeP
Communication with the public provides an opportunity to 
increase awareness and involvement of the broader community. A 
primary objective of this process is to help inform decisions with 
the experience and knowledge of a much wider group of “experts” 
than those included in a formal decision process (Dietrich and 
Schibeci, 2003; State of Victoria, 2005; Nuffield Council on 
Bioethics, 2012). There also is the hope that public understanding 
will increase public acceptance when a new technology has been 
evaluated and deemed safe by national biosafety decision makers, 
although this relies on an underlying trust of the system (Frewer 
et al., 2004; Sinemus and Egelhofer, 2007; Siegrist, 2008).
Developers and introducers of new technologies (the appli-
cants in a regulatory system), clearly believing in the value of their 
technology or product, may employ public engagement as a way 
to gain support and acceptance of a technology either prior to 
or during regulatory review. In fact, the Convention on Access 
BOX 1 | Fundamentals of public involvement.
Effective engagement involves all important stakeholders including product developers, product users, and regulators – basically all persons or entities that could 
be directly affected by the new technology. In order to be effective, this engagement must be timely, transparent, and trustworthy. However, gathering public input 
for a case-by-case decision process may be driven by legislation that defines and sets the criteria for the extent and type of information that will be gathered, or the 
consultation may be conducted voluntarily.
The diagram below identifies this continuum of potential public involvement from (left) being a partner in an ongoing process by the applicant to gain and maintain 
a social license or to discover alternatives matching community preference through two-way communication and mutual learning; through the (center) opportunity 
for clarifying societal values through consultation on the decision framework, for example, and learning public opinion, with some educational efforts; through (right) a 
more traditional governmental call for comments within a set framework, to achieve compliance with consultation requirements at a set point in time. This continuum is 
from the public having significant influence on a decision to a more unidirectional communication of information and decisions. (The International Association for Public 
Participation (IAP2) schematic,1 the public participation spectrum used by the US Environmental Protection Agency (EPA),2 the State of Victoria (2005), and others, 
shows the continuum as moving, in a similar direction, from the steps to empower, collaborate, involve, consult, or inform.) The proposed response to the question of 
who is responsible to achieve these may be debated, but practical experience indicates that regulators should be increasingly involved in those consultations indicated 
in legislation but decreasingly involved in other formats.
While these factors are well understood on paper, implementation of an effective public engagement plan is both complex and challenging. Complexities include 
communicating with multiple groups each of which enters the process at a different level of knowledge and understanding of the technology, biases, and sometimes 
a different set of goals for the interaction.
One of the greatest challenges is transparent and effective communication of both the potential benefits and potential risks of a product developed using a highly 
technical process to a public that may be skeptical of the benefits and risk averse. In fact, research suggests that case specific considerations can reveal nuances in 
public acceptance and concerns (Frewer et al., 2013). Other challenges include short timelines, inadequate funding, and limited expertise or experience in seeking, 
gathering, interpreting, and communicating public input. While the complexities and challenges of public engagement can be somewhat daunting, there are several 
examples of how they have been overcome to allow the biosafety decision-making process to move forward.
1 http://www.iap2.org/
2 http://www2.epa.gov/international-cooperation/public-participation-guide-introduction-guide
TABLe 1 | Questions to national policy makers, regulators, and 
developers or introducers of biotechnology on engaging the public.
1. Why do you seek public input and what value have you derived from it?
2. What approaches have you found to be most effective in obtaining and 
addressing public input?
3. What have you found to be least effective?
4. What have been the most significant challenges you have experienced? And 
what guidance would you offer others on addressing these challenges?
5. What particular aspects of public engagement haven’t you worked out how 
to do yet?
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decision-making consultation. This practice varies considerably 
with the nature of the technology and the societal context into 
which it would be introduced.
engagement of industry with the Public
Successful commercialization of genetically modified organisms 
(GMOs) requires not only regulatory approval but also public 
acceptance. Regulatory approval is obtained by following guidelines 
and submitting dossiers to government agencies. Establishing a 
consistent, coherent, and continuous two-way dialog between the 
developers of GMOs and the general public to help support public 
acceptance has been an elusive goal. In terms of communicating 
information regarding the safety of GMOs, industry, and other 
developers have typically used presentations at scientific meetings, 
publications in scientific journals, publicly available submissions 
made to regulatory agencies, and static online content. In most 
to Information, Public Participation in Decision-Making and 
Access to Justice in Environmental Matters, frequently referred to 
as the Aarhus Convention (UNECE, 1998), encourages informa-
tion exchange between applicants and the public prior to official 
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cases, communication efforts are made by individual develop-
ers, although groups, such as CropLife International and the 
Biotechnology Industry Organization, will sometimes provide 
information representing multiple developers. These efforts have 
met with varying levels of success depending on the topic and the 
audience but did not result in fully effective public engagement.
In 2013, GMO Answers2 was developed and then launched 
by a group of six companies (BASF, Bayer CropScience, Dow 
AgroScience, DuPont, Monsanto, and Syngenta) involved in 
the development of genetically modified (GM) crops as part 
of the Council for Biotechnology Information. In addition 
to the founding companies, there are 11 “supporting part-
ners”  –  mostly crop associations that support the concepts 
behind the project. The goal of this new website and effort was 
to increase the level of conversation among interested parties. 
The website provides basic information about GM crops, links 
to studies and articles, and easy-to-read explanations and 
responses to frequently asked questions or topics. Perhaps, 
the most important function of the website (and associated 
Facebook and Twitter links) is that it provides an easily acces-
sible location where questions about GM crops can be asked 
and answers are then provided by one or more experts. The 
experts include academics, trade organizations representatives, 
farmers, nutritionists, and developer company scientists. The 
source(s) of each answer is identified on the website. Questions 
that have been asked include not only those related to human 
and environmental safety, but also those regarding product 
development, economics, trade, and more.
As of March 2015, about 800 questions had been asked and 
answered on the website. In general, about 40% of responses are 
from industry experts, 30% from academic or other non-industry 
experts, and about one-quarter from the moderator (often because 
the question had already been asked and the query can simply be 
responded to by a link to the previous answer). While it is difficult 
to measure the direct success of this effort, the site has hosted 
740,000 visitors since launching in 2013. In terms of broader and 
continued communication, the primary drivers for website traffic 
are links from Facebook and Twitter and approximately 30% of 
site users are returning visitors. Public engagement is expected 
to become broader as GMO Answers expands to other languages 
and communication pathways – for example, a Japanese language 
version of the GMO Answers website recently became available, 
other language sites are currently under development, and GMO 
Answers maintains both an active Twitter feed and Facebook page.
Where in the past, the primary engagement was between bio-
technology developers and regulatory agencies, GMO Answers 
has begun to broaden the conversation so that it includes the 
general public. The act of responding to public queries, in addi-
tion to questions from regulators, increases both the breadth 
and depth of the interaction in a way that should increase public 
understanding, if not acceptance, of the technology. This is an 
example of improved involvement of the public, although educa-
tion and access to information do not necessarily imply increased 
understanding and acceptance.
2 http://www.gmoanswers.com
engagement by Non-Regulatory 
Biotechnology Organizations in Sub-
Saharan Africa
Sub-Saharan Africa is in the early stages of developing regulatory 
frameworks for approving the commercial release of GM crops, 
including regulatory capacity to capture and address public 
input. One striking observation about sub-Saharan Africa from 
an external observer is the number of countries with public or 
quasi-public organizations or non-governmental organizations 
(NGOs), which were set up to provide information, education, or 
opportunities for engagement on biotechnology. The existence of 
these organizations, which are external to the regulatory frame-
work, appears to be a result of varying factors: the emergence 
of the technology in relation to political contexts; the desire 
to consider potential benefits as well as risks to the countries 
involved from a perspective of scientific and human capacity, and 
socioeconomic development (McLean et al., 2012); and the lack 
of resources within regulatory bodies to manage any additional 
requirements of engagement.
There are several organizations that address issues of com-
munication with the public as part of a broader remit to enhance 
biosafety capacity throughout the region. These organizations 
include the African Biosafety Network of Expertise under the 
New Partnership for Africa’s Development (NEPAD), the Open 
Forum on Agricultural Biotechnology in Africa, the Program for 
Biosafety Systems under the International Food Policy Research 
Institute, and the International Centre for Genetic Engineering 
and Biotechnology.
Regulatory biosafety legislation in many countries within 
sub-Saharan Africa has been shaped by the Cartagena Protocol 
and the African Model Law on Biosafety,3 which support the use 
of risk assessment for decision making but, in the case of the lat-
ter, from a particularly precautionary perspective. Nevertheless, 
the Protocol also acknowledges the tension between the need to 
protect human health and the environment from the possible 
adverse effects of the products of modern biotechnology and 
the potential of the technology to promote human well-being, 
particularly in meeting critical needs for food, agriculture, and 
health care. Ongoing African biotechnology research and the 
political support emerging for this has been summarized in 
recent publications (Karembu et al., 2009; Chambers et al., 2014), 
including the popular press. To generalize, historically the debate 
on policy has been largely influenced by both “pro” and “con” 
interests external to the region, as the general public relies on 
media to form opinions on complicated scientific questions. The 
existence of government and independent groups supporting 
education, communication, and stakeholder involvement is 
salutary to the degree to which the objectives and agendas of the 
organizations are made clear.
The International Service for the Acquisition of Agri-biotech 
Application has provided information on commercialization 
of GM crops since their first planting in 1996.4 Another early 
organization, set up close to the beginning of biotechnology 
3 http://hrst.au.int/en/biosafety/modellaw
4 http://isaaablog.blogspot.co.uk/
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commercialization, was AfricaBio in South Africa, a non-profit 
stakeholders’ association which plays the role of advocate of the 
potential benefits of technology, as well as promoting appropriate 
biosafety and regulation. A case study of AfricaBio (UNECE, 2013) 
acknowledged its good practices in involving local farmers as the 
facilitators, involvement of the entire rural community, and access 
to the yield results of the GM crop, in this case, maize. It was criti-
cized for presenting information from one perspective. Although 
a self-stated advocate, it can provide scientifically based materials 
in an accessible manner for better understanding of biotechnology.
The Africa Harvest Biotechnology Foundation (AHBFI), 
established in Kenya in 2002, has acted in an advocacy role with 
often underrepresented stakeholders. The primary focus has been 
on delivering solutions to hunger and agricultural challenges by 
partnering, but more recently, a 10-year strategy has restated the 
need for deeper engagement beyond delivery of a transparent and 
scientifically supported message (AHBFI, 2012).
Other organizations are more like industry associations, such 
as the African Biotechnology Stakeholders Forum5 in Kenya. 
More quasi-public entities with ongoing government support, 
as well as other funders, include the Uganda Biotechnology and 
Biosafety Consortium (UBBC). The National Biotechnology 
Development Agency was established by the Nigerian govern-
ment with the mandate to implement a policy specifically for 
“promoting, coordinating, and setting research and development 
priority in biotechnology for Nigeria”6; its mandate includes 
influencing future regulatory and legislative language.
This range of organizations forms a critical part of public 
engagement in their countries and regions, and, in some cases, 
global networks. The two decades since GM crop commercializa-
tion began also have seen significant changes in the role of the 
public in policy formation and regulatory considerations. As one 
publication (Navarro et al., 2013) puts it, science communication 
is not enough. These organizations in sub-Saharan Africa appear 
to be developing more locally appropriate methods for involving 
the public and encouraging input from the most critical groups 
affected by the decisions.
iNvOLviNG THe PUBLiC iN DeCiSiON 
MAKiNG
Guidance on environmental Risk 
Assessment for GM Animals in europe
Presently, European legislation on field release of GMOs is cov-
ered in Directive 2001/18/EC of the European Parliament and of 
the Council of March 12, 2001 on the deliberate release into the 
environment of GMOs, and related regulations.7 The framework 
5 http://absfafrica.org/
6 http://www.nabda.gov.ng
7 In order to rationalize the values expressed by individual Member States which are 
blocking field release for reasons other than human safety and the environment, 
with the implementation of the biosafety framework (European Commission, 
2015), the Commission has now added Directive (EU) 2015/412 of the European 
Parliament and of the Council of 11 March 2015 amending Directive 2001/18/EC 
as regards the possibility for the Member States to restrict or prohibit the cultiva-
tion of GMOs in their territory (OJ L 68, 13.3.2015, p. 1).
relies on the European Food Safety Authority (EFSA) to make 
scientifically based recommendations regarding applications 
(European Commission, 2015). This framework gives explicit 
directions only on assessing the risk from GM plants for import 
or cultivation for food or feed, but not yet on GM animals to be 
raised in the European Union territory.
In 2007, the European Commission requested that EFSA 
initiate a process to address environmental safety of GM ani-
mals, initially to complement guidance on risk assessment of 
GM animals in regard to food and feed (EFSA, 2012). The role 
of guidance documents has been to assist applicants in under-
standing requirements for applications, in line with the existing 
European legislative framework (EFSA, 2013a). Documents 
have been developed, or revised, as legislation has changed or 
experiences with applications have provided new insights. The 
development of guidance on environmental risk assessment 
involved review of existing materials, definition of the scope 
(including proposed categories and likely cases of GM animals 
ready for the European market in the near term), and identifica-
tion of experts. Some materials were compiled by contracted 
consultants (Fera, 2010; Umweltbundesamt, 2010; University 
of Hull, 2010), and a draft Guidance outline of content was 
prepared by the EFSA GMO Unit.
New material was then developed by three working groups 
(WGs), convened for the purpose, over the course of around 
2 years. The WGs focused on their respective areas of expertise 
in application to GM fish, GM mammals and birds, and GM 
insects, and jointly prepared material on the overarching and 
cross-cutting sections of the guidance. An important part of the 
process was a public consultation to allow stakeholder input, 
which was then considered by the same WGs, the relevant EFSA 
staff (the GMO Unit) and the EFSA GMO Panel. The EFSA GMO 
Panel endorsed the draft scientific opinion, which went to the 
public consultation process (EFSA, 2013b).
Consideration was to be given to all “scientifically relevant” 
comments, but not to risk management, risk/benefit analysis, and 
ethical and socioeconomic aspects raised in comments, which are 
outside the EFSA purview. The draft opinion was posted on the 
EFSA website,8 now available under closed consultations, and a 
comment period was open from June 21 to August 31, 2012. Efforts 
were made to publicize the process and encourage comment. A 
template and instructions for submitting comments supported 
the process. Specific criteria were given to define what would, and 
would not, be considered from public input: only submissions 
relevant to the document, within the deadline, on the template 
provided; no complaints against institutions, individual persons, 
or offensive material; and only comments related to policy within 
the scope of EFSA’s activity.
Twenty-five entities  –  including national governmental 
organizations and NGOs, research institutes and universities, 
industry groups, and individuals  –  submitted 720 comments 
in response to this opportunity. All comments were published 
(EFSA, 2013b), including those which did not meet the stated 
criteria for receiving consideration. Only 10% appeared to be 
8 http://www.efsa.europa.eu/en/consultationsclosed/call/120621.htm
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repetitions of a phrase likely provided by a single source to those 
submitting: “EFSA is not competent to assess environmental risks 
as it has no remit or expertise in this area” or similar wording. 
The identity of the stakeholder was published, except when an 
individual person, in which case the comments were included 
but the individual was anonymous. The vast majority of the 
720 comments arose from within the European Union Member 
States, with half identified as from Germany (195 of which were 
from the Max-Planck-Institut für Evolutionsbiologie – the Max 
Planck Institute for Evolutionary Biology) and one-third from the 
UK (143 of which were from GeneWatch UK). Comments were 
also received from individual(s) listed as from the USA, two US 
NGOs, and an agency in the Government of Canada.
A significant portion of the entire time involved in devel-
oping guidance went into considering and responding to 
the public input. The EFSA GMO Unit (staff) organized the 
comments for the WGs and therefore sorted the relevance and 
topic prior to consideration by the WG experts. However, the 
WGs invested many hours reviewing and rewriting in response 
to the comments. Significant improvements to the guidance 
included clarification of the scope to include both intentional 
and accidental release to the environment within the European 
Union (but not confined use in general), greater consistency of 
terminology and concepts across the various chapters, enhanced 
guidance on the environmental risk assessment step of problem 
formulation and clarity of objectives of each step, and closer 
alignment of the guidance to the relevant European legislation 
(Directive 2001/18/EC) (European Commission, 2001), as well 
as better explanation of sections considered unclear (EFSA, 
2013b).
In summary, this process of developing guidance for assess-
ing potential risks from the introduction of GM animals to 
the environment (EFSA, 2013a) included a significant effort to 
engage with the affected national governments and public, but 
also allowed comment from outside the European Union. The 
entire process took just over 6  years. The improvement in the 
document was acknowledged by EFSA, but opponents to any 
GMOs or those who question EFSA’s role in preparing guidance 
will remain frustrated since the forum was not meant to address 
the overall biosafety framework which assigns EFSA its role.
This stands in contrast to the 2003 “GM Nation?” consultation 
covering the UK in several ways: the UK consultation was to allow 
public comment on the overall issue of commercializing biotech-
nology; the eventual effect of the public input was not clearly 
defined in advance; and participation was largely self-selected 
(as with the EFSA consultation) but was supplemented by focus 
groups of more representative populations (although these were 
later found to be methodologically imperfect) (Pidgeon et  al., 
2005; UNECE, 2013).
The ongoing collection of input on the policy and framework 
(although external to the regulatory body) described below for 
Australia, and the process led in New Zealand by the Royal 
Commission on Genetic Modification (2001) have attracted 
wide participation over time. The latter collected over 10,000 
written comments and numerous opinions at public workshops 
to conclude that the country should proceed cautiously with the 
introduction of GMOs due to public concern. Such a process is 
designed to elicit public opinion on broader questions than the 
specifics of risk assessment or particular cases. The purpose of the 
EFSA guidance was to clarify what information would be required 
from applicants in order to evaluate a release of a GM animal 
into the environment in the territory of the European Union and 
how that information would be considered. Comments on the 
overall policy, legislative framework, and competency of each 
component of the framework were irrelevant to the consultation 
yet dominated the submitted comments.
GM Crops in the Philippines
The Philippines has been heralded as the first Asian country 
with a biosafety regulatory framework, which was put to public 
consultation at the time (NAST, 2009), and commercial approval 
of a major GM crop (Panopio and Navarro, 2011). The Philippine 
government’s policy statement9 makes clear the official vision for 
biotechnology: “We shall promote the safe and responsible uses 
of modern biotechnology and its products as one of the means to 
achieve food security, equal access to health services, a sustain-
able and safe environment and industry development.” While the 
regulatory system has been challenged, it has generally worked 
due to the commitment to scientific criteria and transparency 
in decision making (Halos and Soriano, 2014). For example, 
a website was established early on to facilitate public access to 
documents related to applications (NAST, 2009).
However, some local government units (LGUs) took a negative 
stance against GMOs, even going so far as to declare themselves as 
GMO-free zones (Cabanilla, 2007). The legal authority for LGUs 
to have autonomy from national government in some aspects 
was given by the Local Government Code (Republic Act 7160 of 
1991), which coincidentally coincided with the early field trials 
of GM crops. This division of authorities, along with involvement 
of international NGOs, has complicated the public engagement 
process and led to varying views on its legitimacy. Increased 
capacity building for local government is considered one way to 
improve understanding at that level in the future (NAST, 2009).
GM Corn
The first confined field trials in the Philippines were for transgenic 
corn, conducted under different permits by two international 
corporations. As is often the case, the evolution of the regulatory 
system and development of the steps toward commercial release 
were spurred on by these early applications (NAST, 2009). The 
GM corn cases were also cited as a turning point for the National 
Committee on Biosafety in the Philippines (NCBP) in their under-
standing of the range of stakeholders interested in their decisions. 
While initial engagement was with the applicants – developers 
and introducers of the advances in biotechnology  –  it was the 
opponents or the public at large who required in depth education 
and communication opportunities. This was a shift in approach 
for the NCBP (NAST, 2009).
Experiences with field trials and regulatory approval of GM 
corn are described by Panopio and Navarro (2011) as a “drama.” 
9 A full copy of the policy statement appears at http://www.bic.searca.org/info_kits/
policies/policy_statement.htm
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Cabanilla (2007) refers to the protests and destruction of crops 
during the period when GM corn was in confined field stud-
ies as being conducted by “militant groups,” listing those as 
Kilusan ng Magbubukid sa Pilipinas (KMP, literally translated 
as Peasant Movement of the Philippines); MASIPAG (acronym 
for Magsasaka at Sayantipiko Para sa Ikauunlad ng Agham 
Pangagrikultural), South East Asia Regional Initiatives for 
Community Empowerment (SEARICE), Greenpeace, and the 
Philippine Greens. However, these more radical positions did 
not take away the interest in the production sector. Presently, 
six transgenic events of corn have been commercially released in 
the country. In <10 years after the first commercial production 
of GM corn was approved, the Philippines was reported to be a 
self-sufficient producer of corn and one of the larger producers of 
GM crops globally (Fernandez, 2015).
Bt Eggplant
One of the more publicized cases in apparent public reaction 
to regulatory approval of a GM crop is Bacillus thuringiensis 
(Bt) eggplant or, as locally known, Bt talong. In the Philippine 
biotechnology regulatory system, public information and par-
ticipation applies to all stages of the biosafety decision-making 
process starting from the time the application is received. Early 
on in the process, Institutional Biosafety Committees are required 
to be established in institutions involved in genetic engineering 
research. A committee must be composed of at least five mem-
bers – at least three scientists and two community representatives 
who will represent the interest of the surrounding community 
with respect to health and protection of the environment. 
Institutions applying for field testing of a GMO are required to 
notify and invite the public to give comments on the proposed 
activity. A Public Information Sheet (PIS) about it must be posted 
for at least 3 weeks in three conspicuous places in the barangay 
(village) where the study is to be conducted. For application for 
propagation, the information sheet must also be published in two 
newspapers of general circulation.
The initial public engagement for this case was aimed at 
informing the public of the upcoming regulatory decision and 
the potential benefits of the approval for Bt eggplant multiple 
field trials. The contrast between using this innovation and the 
dangers of continual pesticide use was documented clearly [e.g., 
Panopio and Mercado (2010)]. Farmers facing the pest problems 
were reported to be supportive and eager for the crop to be com-
mercialized (Subbaraman, 2011).
Campaigns against the trials were conducted by Greenpeace 
Southeast Asia, the Magsasaka at Siyentipiko para sa Pag-unlad ng 
Agrikultura (Farmer-Scientist Partnership for Development – its 
acronym, MASIPAG, means active or energetic in Tagalog) 
and Sibol ng Agham at Teknolohiya (Wellspring of Science and 
Technology, SIBAT). The collection of public opinion has been 
documented to be heavily influenced by external antibiotech-
nology interest groups. Their efforts, which culminated in the 
Philippines Court of Appeals stopping the trials in May 2013, 
relied largely on greater resources and organization than the 
proponents of the technology possessed (Laursen, 2013).
Analysis suggests that the focus on the technology for achieving 
a beneficial outcome and the scientific advance it represented were 
ineffective for achieving public understanding of the risk/benefit 
involved (Escano, 2013). Messages were considered to be too tech-
nical. The message of further documentation of the benefits to 
farmers [e.g., Gerpacio and Aquino (2014)] was possibly lost, as 
the pesticide regime is a familiar risk and the fear of the unfamiliar 
was a key point in opposing media. As the legislative framework 
did not limit public input to those affected by the technology and 
there is no mechanism for understanding the source of changes 
in opinion, there is nothing to prevent this situation. Rather than 
relying on scientific debate, the input from Greenpeace, for exam-
ple, has been categorized as playing on emotions (Ropeik, 2013).
In this case, the legislative framework almost appears to have 
worked against the public input process. National legislation 
requires informing the public of the conduct of the field trials 
by posting a PIS in areas where the trials will be done. Several 
trials were attacked, damaging the research study. The first delay 
in trials was based on charges that the public consultation was 
not accomplished according to law, although the variation from 
requirements was very minor (Ilano, 2011). Competing jurisdic-
tions between national, regional, and municipal confused the 
process to some extent.
Since the Court of Appeals’ judgment stopping trials, there 
have been public consultations and meetings with farmers to 
attempt to progress scientific understanding and document 
local acceptance.10 In 2014, the Biotechnology Coalition of the 
Philippines was allowed to introduce a petition to the High 
Court noting, “Greenpeace does not have assets or properties 
affected by the Bt talong field trials. Greenpeace has no actual, 
direct and immediate stake in the subject of the litigation.”11 The 
decision of the Supreme Court of the Philippines on the Motion 
for Reconsideration filed by the respondents to the case is still 
pending at the time of this article.
The Philippine regulatory agencies have increased the interac-
tions with stakeholders and allowed concerns raised by various 
groups to be introduced into the consultation process. However, 
they have also remained clearly committed to a science-based risk 
assessment and decision-making process. The public good of the 
benefits to the farmers is considered much greater than the cost, 
in all senses, of the regulatory process (Halos and Soriano, 2014). 
The challenges of this country’s approach would not recommend 
it as a model of success, yet stakeholders have had a voice, even 
through the court system, at the time of formation of the biosafety 
framework and through to the case-by-case decision system today.
The Australian Perspective
The Australian approach to communication with the public about 
the release of a GMO into the environment is determined by 
legislation and by administrative processes established to achieve 
consistent, sound regulatory decisions.
The Australian gene technology legislation requires informing 
the public on the regulatory decision-making process and seek-
ing public input into that process. These aspects of openness and 
10 http://www.businessmirror.com.ph/farmers-plead-with-sc-junk-case-vs-bt- 
eggplant/
11 http://www.interaksyon.com/article/95059/sc-allows-biotechnology-group- 
to-intervene-in-bt-eggplant-case---bcp
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transparency, together with consultation, are intended to build 
trust in the regulatory system. Therefore, communication extends 
to a broad range of stakeholders, such as the license (or “licence” 
as indicated in Australian legislation) applicant/holder, the Gene 
Technology Technical Advisory Committee, the Minister for 
the Environment, other federal regulatory bodies, and State and 
Territory governments, as well as the public. Reviews and con-
sultations on the legislation and policy governing the Australian 
regulatory scheme are conducted by a policy section of govern-
ment under the oversight of a Federal/State Ministerial Forum. 
The regulatory body, the Office of the Gene Technology Regulator 
(OGTR), is responsible for administering the regulatory scheme, 
as well as advising the policy makers on its effectiveness, possible 
improvements, and other technical questions.
Public input is achieved through engagement at public meet-
ings and access to the regulatory agency via a toll-free telephone 
number, email, and letter. Nevertheless, the primary means of 
communication is through submissions sought on a consultation 
version of the main document used in decision making, namely, 
the risk assessment and risk management plan. This document 
is prepared for each license application to approve a field trial, 
clinical trial, or commercial release of a GMO.
Development of efficient administrative processes to support 
decision making has led to applying similar approaches and 
language for seeking public input, irrespective of the type of 
organism, novel trait, or end use. However, public responses to 
different license applications may vary in unexpected ways. This 
is illustrated by contrasting two GMOs that were approved for 
environmental release. One case concerns the commercial release 
of GM cotton throughout Australia, while the second case relates 
to a clinical trial of a GM vaccine for cholera.
GM Cotton – Public Submissions
In 2014, a consultation risk assessment and risk management 
plan for a commercial release of GM cotton with insect resistance 
and herbicide tolerance was prepared and public input sought 
over an 8-week period.12 Only four submissions were received. 
Three submissions opposed approval of the release, while one 
supported its approval. Although this number of submissions 
is low, it is consistent with the relatively low concern expressed 
about all GM cotton license applications. In addition, the types 
of comments in the three submissions that did not support 
approval raised concerns similar to those raised for other GM 
cotton releases, including lack of confidence in the applicant’s 
data and the reliance of decision making on that data; request 
for additional information on potential adverse effects; lack of 
information on long-term and cumulative effects; possible effects 
on bees and other beneficial pollinators; purported insufficient 
evaluation of health and environmental safety issues; and con-
cerns about increased herbicide use.
GM Cholera Vaccine – Public Submissions
A consultation risk assessment and risk management plan for 
a clinical trial of an oral GM vaccine for cholera limited to a 
12 http://www.ogtr.gov.au/internet/ogtr/publishing.nsf/Content/DIR124
maximum of 1000 volunteers was also released for public input 
in 2014.13 In contrast to the GM cotton case, 68 submissions (all 
opposing the trial) were received, as well as many direct calls to the 
regulatory agency and many comments on social media. This level 
of response was unexpected as GMOs used as human therapeutics 
(e.g., GM vaccines) usually raise less concern than GM crops.
Some of the concerns included opposition to vaccination in 
general; lack of relevance due to limited occurrence of cholera in 
Australia; potential for horizontal gene transfer; purported insuf-
ficiency of data; the possibility of inadvertent exposure of people 
to the GM vaccine through disposal into sewage and dump sites 
(i.e., through nappies); issues with the design of the trial (e.g., 
ethics of using children, long-term effects, compensation issues, 
meaning of results, or need for independent oversight of partici-
pants’ safety); and disputing the need to keep certain commercial 
information confidential.
Some of the marked interest in this particular license applica-
tion can be attributed to a message in social media, which errone-
ously claimed that there would be aerial spraying of the vaccine. 
This message was amplified primarily among anti-vaccination 
groups, but did not appear in mainstream media. In addition, 
the use of technical/bureaucratic language may have obscured the 
message.
Public Input to Case-by-Case Decisions Informing 
the Decision-Making System
Consultation with the public on applications for the proposed 
environmental release of a GMO has been successful in provid-
ing the public with the opportunity to contribute directly in the 
decision-making process. As demonstrated by the two cases 
illustrated above, the number of responses can vary substantially 
according to the type of GMO and level of concern.
In addition, expression of the varied concerns, issues, and 
values of the public contributes to improvements in regulatory 
decision making. Some of the major lessons that have emerged 
from public input to decision making on GMO releases during 
14  years of operation under the current Australian regulatory 
system include
• Only a small proportion of the Australian public has expressed 
concerns through submissions on individual license appli-
cations, but these mirror the level of concern reported in 
government surveys on public attitudes to biotechnology.
• Many concerns fall outside the scope of the legislation.
• Many concerns do not accord with the facts but reflect certain 
values and world views.
• The public is a conglomerate of distinct groups with different 
interests, concerns, and preferred channels of communication.
• Greater effort is required to communicate with the public in 
simple, clear language.
• Openness, transparency, and accessibility need to be demon-
strated in meaningful and practical ways.
The Australian process varies from many others in its ongoing 
consideration of issues regarding the framework and not only the 
13 http://www.ogtr.gov.au/internet/ogtr/publishing.nsf/Content/DIR126
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current case decisions. It may be worth noting that the OGTR 
is staffed by over 40 full-time-equivalent staff. The resources are 
greater than in many developing countries.
DiSCUSSiON
Public input to biosafety decisions can be a valuable resource for 
improving risk assessment, communication, and risk manage-
ment. Yet trying to use public engagement as a means to legitimize 
the process can be counterproductive. For whichever objective, 
public input is sometimes a painful process. The need to capture 
and address public input is a responsibility under the Cartagena 
Protocol (Article 23) and most national biosafety frameworks. 
Specific guidance on how to achieve this is not provided, however. 
The responsible parties for each step along the continuum of 
involvement and the approach to consultation are dictated by the 
national biosafety framework, the available financial resources, 
capacity, and interest (UNECE, 2013).
Due to the complexity of many of the issues, public education 
and enabling initiatives can play an important role in supporting 
input to biosafety decisions (Rollin et  al., 2011). Realistically, 
few regulatory agencies can serve as educator, communicator, 
and regulator. The applicant, who is usually the developer of 
the technology, is a necessary source of information in order 
to ensure accuracy about the technology or product and the 
intended study, release, or commercialization plans. A two-way 
dialog between industry and the public facilitates improvement 
in risk communication and may highlight areas for improved 
assessment or management. The landscape of biosafety informa-
tion and education sources in sub-Saharan Africa has shown the 
need for parties outside the confines of regulatory agencies to 
provide ongoing education and representation of stakeholders, 
particularly when societies are eager for benefits that address 
basic health, food security, and economic development, but may 
be open to external influences.
The importance of defining in advance the goal of seeking 
input cannot be overemphasized. Equally, it is important to draw 
a distinction between public engagement for formation of policy 
and development of the decision-making process and public input 
to a specific case within that framework. Frequently, comments are 
submitted on the former when the consultation is addressing the 
latter. For those decisions which do relate to the policy or overall 
decision framework, such as the guidance on risk assessment of 
GM animals in Europe or on the decision process in Australia, 
enhanced decision-making frameworks may have long-term 
effects.
The cases discussed show how interest groups, often external 
to those stakeholders affected by a decision, can use the opportu-
nity for public input as a battlefield to advance their values. This 
has certainly been the case for the Philippines where the biosafety 
framework is open to input from any sector, and NGOs have used 
legal means outside the framework to cause delays to approved 
trials for a GM crop which, if deployed, could contribute to a 
marked reduction in use of chemical pesticides. Herring (2008) 
in a perspective piece referred to the “archetypal deep disjuncture 
between the ideas and interests of global activists and the farmers 
they claim to represent.”
Those faced with decision making within a prescribed frame-
work will benefit from criteria and guidance on who constitutes 
the public to target for consultation.
Reaching the public and gathering input has many challenges 
but can be achieved through various means. The government then 
must establish and implement a logical and transparent system for 
what it will require and how it will evaluate the scientific data that 
form the basis of a sound biosafety decision. Guidance to regula-
tors on the scope of feedback to consider is crucial. Otherwise, the 
process can be dominated by value-laden viewpoints that cannot 
be affected by new information, education, or engagement. As 
Rollin et  al. (2011) note, in some cases “information activates 
already existing attitudes, rather than changes them.”
Finally, conclusions and responses to consultation should 
be communicated back in an accessible manner. This serves to 
inform the public but also builds trust in the process, for those 
taking the time and trouble to provide input. The fact that this 
remains a weak link in most experiences indicates that further 
work on effective communication of this type would be beneficial. 
An interesting side note to this is the consideration of public 
involvement in ongoing monitoring of risks and benefits, which 
also requires effective feedback mechanisms operating over time 
(Ching, 2007).
In conclusion, several general practices have proven to be 
effective for involving the public in decisions on specific cases: 
(1) utilizing government and independent groups to facilitate 
public education, communication, and involvement about 
complex technologies beyond usual public understanding; (2) 
defining in advance the goal of seeking input; (3) identifying the 
critical public groups from which input is needed, and effectively 
communicating to these both the consultation goals and how 
input will be gathered and used; (4) using a logical, transparent 
approach to gathering and assessing scientific data that will be 
used in making the biosafety decision; and (5) communicating 
findings and response to input using clear and simple language. 
These practices create a foundation for systematic methods to 
gather, acknowledge, respond to, and even incorporate public 
input. Applying such best practices will increase transparency in 
terms of the scope and limits of the consultation and will optimize 
the value of any input from the public. This also reduces the 
sociopolitical pressures on regulatory decision makers who are 
working within an already established framework, thereby allow-
ing decisions to be made based on the criteria under their remit.
It has been observed that a number of countries treat actions 
or scope suggested in the Cartagena Protocol, or in other guid-
ance developed outside the process of the CBD Conference of 
Parties [e.g., UNECE (1998, 2003)], as legally binding require-
ments within their own national legislative framework. This can 
lead to onerous expectations. In fact, it can be counterproductive 
to attempt public participation without sufficient resources to 
conduct the process, capacity among both facilitators and the 
participants, ability to design a proper process which offers 
transparency, and a climate of integrity.14 Financial resources 
14 http://www2.epa.gov/international-cooperation/public-participation-guide- 
introduction-guide 
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for implementing Article 23 are considered to be insufficient 
in many cases (Biosafety Clearing House, 2014b). In reality, it 
is often the resources available that determine the approach. 
This has been addressed to some degree through creative coali-
tions, public and private mechanisms for providing educational 
materials, and opportunities for public awareness raising and 
involvement. Supporting these broader processes also may 
alleviate the pressures on regulators who, the authors believe, 
should be limiting their deliberations to science within their 
regulatory mandate.
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